Therapie der neovaskulären altersbedingten makuladegeneration mit Ranibizumab/Lucentis™

Translated title of the contribution: Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis™

Stephan Michels, P. J. Rosenfeld

Research output: Contribution to journalReview articlepeer-review

34 Scopus citations


Vascular endothelial growth factor (VEGF) is considered to play an essential role in the pathogenesis of age-related macular degeneration due to its vascular permeability-inducing and angiogenic properties. Ranibizumab, a small antibody fragment designed to competitively bind all VEGF isoforms, passes after intravitreal injection all retinal layers reaching the retinal pigment epithelium-choroid complex. Experimental animal models showed the drug to be safe and effective. Subsequently, Phase I/II clinical trials conducted in patients with neovascular AMD demonstrated a good safety profile, and a significant functional benefit. Ranibizumab therapy repeated every four weeks for the treatment of neovascular AMD is currently in Phase III clinical trials. Combination therapy trials aiming for improved treatment durability and effectiveness are currently ongoing as well as new treatment strategies using intermittent, optical coherence tomography (OCT) guided therapy. Anti-VEGF therapy using Ranibizumab is a promising new treatment option for neovascular AMD.

Translated title of the contributionTreatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis™
Original languageGerman
Pages (from-to)480-484
Number of pages5
JournalKlinische Monatsblatter fur Augenheilkunde
Issue number6
StatePublished - Jun 1 2005


  • Age-related macular degeneration
  • Angiogenesis
  • Choroidal neovascularization
  • Ranibizumab
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis™'. Together they form a unique fingerprint.

Cite this